Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.

In this episode, Sarah Hughan unpacks clinical stage biotech company AdAlta (ASX1AD), set to unlock value from its AD-214 asset and expand its pipeline through its “East to West” cell therapy strategy in 2025.

Tune in to find out what to look out for in the new year.

 

This video was developed in collaboration with AdAlta, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in